Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 7 Nov 2026
Early cancer detection or prevention

Real-world adoption of circulating tumor DNA testing and adjuvant treatment decisions after radical cystectomy for muscle-invasive bladder cancer.

Doctors are increasingly using blood tests to guide cancer treatment decisions, though tumor stage remains the strongest factor guiding therapy choices so far.

Real-world data from 4,533 MIBC patients showed rapid uptake of post-cystectomy ctDNA testing (16% increase per quarter), driven by high-risk pathology. Despite the unadjusted association between ctDNA positivity and adjuvant therapy use, the association was attenuated and non-significant after multivariate adjustment, revealing that pathologic risk stage currently dominates clinical decision-making over ctDNA result alone.

What the study was

Study design
retrospective_cohort
Category
early_cancer_detection_liquid_biopsy
Maturity
Validated
Journal
ESMO Open

Why it surfaced

First large real-world study of ctDNA adoption in MIBC; reveals gap between ctDNA test uptake and its actual influence on treatment decisions; important calibration data for liquid biopsy clinical translation.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.